Poseida Therapeutics Announces Carl June, M.D., to Chair Immuno-Oncology Scientific Advisory Board

SAN DIEGO, March 23, 2021 /PRNewswire/ — Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced the appointment of distinguished scientist Carl June, M.D., who will serve on Poseida’s Scientific Advisory Board (SAB). The SAB provides advice and counsel on the research and development efforts that drive the Company’s innovative cell and gene therapies.